http://www.nlm.nih.gov/databases/alerts/sickle_cell.html
Drug Treatment for Sickle_cell Anemia Clinical Alert:
Drug Treatment for Sickle_cell Anemia National Heart, Lung,
and Blood Institute (NHLBI) today announced a drug treatment for sickle_cell anemia.
Although the exact mechanism of action in sickle_cell anemia is_understood not completely,
and Drug Administration to treat sickle_cell anemia although physicians can prescribe it for that purpose.
Hydroxyurea may_not be appropriate for all patients with sickle_cell anemia,
These findings are the results of data analyzed from the Multicenter Study of Hydroxyurea in Sickle_cell Anemia (MSH),
which reduces the frequency of painful episodes or crises in patients with sickle_cell anemia.
Recurrent painful episodes are the most disabling feature of sickle_cell anemia, interfering with education, vocational_training, job retention and psychosocial development.
a life-threatening complication of sickle_cell anemia characterized by chest_pain,
. Although the exact mechanism of action in sickle_cell anemia is_understood not completely,
which are the hallmarks of sickle_cell anemia. Increased levels of fetal hemoglobin inside sickle red_blood_cells may prevent the cells from becoming rigid,
thereby preventing vaso-occlusion. These findings are the results of data analyzed from the Multicenter Study of Hydroxyurea in Sickle_cell Anemia (MSH),
and the Maryland Medical Research Institute (Dr. Michael Terrin) enrolled 299 adult sickle_cell anemia (Hb SS) patients
or=7. 0 gm/dl (pre-enrollment) to 4. 5-5. 0 if reticulocytes Hydroxyurea may_not be appropriate for all patients with sickle_cell anemia,
each sickle_cell anemia patient must be_evaluated carefully before hydroxyurea therapy is_begun,
and other health_problems. Safety of this agent for children with sickle_cell anemia must be_determined. Physicians can prescribe hydroxyurea for the treatment of sickle_cell anemia in their patients,
http://www.ncbi.nlm.nih.gov/genome/guide/HsChr19.shtml
and Sutherland 6 Some diseases associated with chromosome 19 mutations Acute T_cell Leukemia Diamond-Blackfan Anemia Myotonic_dystrophy See OMIM
http://www.ncbi.nlm.nih.gov/disease/Metabolism.html
Obesity Paroxysmal nocturnal hemoglobinuria Phenylketonuria Refsum_disease Tangier_disease Tay-sachs_disease METABOLISM is the means by
http://www.ncbi.nlm.nih.gov/disease/Transporters.html
syndrome Polycystic_kidney_disease Sickle_cell anemia Wilson's disease Zellweger_syndrome TRANSPORTERS, CHANNELS AND PUMPS that reside in cell_membranes are key to maintaining the right balance
http://www.nlm.nih.gov/databases/alerts/sickle97.html
Periodic Transfusions Lower Stroke Risk in Children with Sickle_cell Anemia Clinical Alert:
Periodic Transfusions Lower Stroke Risk in Children with Sickle_cell Anemia National Heart, Lung,
and Blood Institute today announced that periodic red_blood_cell transfusions in children with sickle_cell anemia has_been found to reduce the rate of stroke in those patients.
The study--the Stroke Prevention Trial in Sickle_cell Anemia (STOP)--compared stroke rates in 63 children who received periodic transfusions with 67 children who were getting standard supportive care.
The STOP study also confirmed that transcranial doppler screening can be_used to identify children with sickle_cell anemia who are at high risk for a first-time stroke.
Before screening children with sickle_cell anemia for stroke risk,
and Blood Institute (NHLBI) announced today a treatment that reduces the rate of stroke (cerebral_infarction) in children with sickle_cell anemia. Strokes occur in approximately 10%of children
with sickle_cell anemia. These events can be very debilitating, leading to physical and neuropsychological impairment
Anemia (STOP) proposed to reduce first_time stroke in children with sickle_cell anemia
and their parents. The STOP Trial confirmed that TCD can identify children with sickle_cell anemia at high risk for first_time stroke
and unnecessarily transfused. It is_recommended that centers that wish to start screening children with sickle_cell anemia for stroke risk do studies to compare their current equipment with STOP Trial
and the care of the child with sickle_cell anemia. For more information on the STOP Trial, contact Dr. Robert Adams at 706-721-4670 or the Sickle_cell
and for screening children with sickle_cell anemia to ascertain stroke risk
http://www.nlm.nih.gov/databases/alerts/amd.html
. Participants in the two groups that took zinc also reported anemia at a slightly higher rate;